Screener
Capricor Therapeutics CAPR Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $20.94M-9.9% | $105.42M+266% | $287.85M+2,450% | $19.51M-71.5% | $23.24M+117% | ||
| $217M+118% | $173.19M+49.3% | $30.28M-78.4% | $79.06M+375% | $99.56M+430% | ||
| $242.13M+95.1% | $283.09M+93.6% | $322.94M+97.7% | $100.95M+17.6% | $124.13M+305% | ||
| $36.35M+355% | $28.5M+365% | $18.31M+229% | $11.07M+108% | $8M+42.3% | ||
| $368.74M+176% | $326.28M+112% | $355.95M+109% | $126.44M+36.0% | $133.57M+249% | ||
| $3.08M-36.0% | $3.93M-25.2% | $1.65M-49.6% | $2.72M-58.4% | $4.81M-22.0% | ||
| $12M0.0% | $12M0.0% | $12M0.0% | $12M-8.6% | $12M-22.0% | ||
| $32.96M+16.1% | $33.64M+50.6% | $35.84M+70.4% | $28.15M+37.5% | $28.4M+27.0% | ||
| $89.56M+45,920% | $13.94M+269% | $14.32M+259% | $14.42M+242% | $194.6K-95.6% | ||
| $122.52M+329% | $47.58M+82.2% | $50.16M+100% | $42.57M+72.4% | $28.59M+6.8% | ||
| $58.11K+27.1% | $57.67K+26.2% | $57.37K+25.9% | $45.72K+13.4% | $45.71K+42.9% | ||
| -$379.55M-51.7% | -$338.82M-51.1% | -$304.88M-52.6% | -$274.71M-42.5% | -$250.14M-38.8% | ||
| $246.22M+135% | $278.7M+118% | $305.79M+110% | $83.87M+22.9% | $104.98M+813% | ||
| $368.74M+176% | $326.28M+112% | $355.95M+109% | $126.44M+36.0% | $133.57M+249% |
FAQ
- What are Capricor Therapeutics's total assets?
- Capricor Therapeutics (CAPR) holds $368.7M in total assets, up 176.1% year over year.
- How much debt does Capricor Therapeutics have?
- Capricor Therapeutics carries $91.0M in total debt against $246.2M of shareholders' equity, a debt-to-equity ratio of 0.37.
- How much cash does Capricor Therapeutics have?
- Capricor Therapeutics holds $20.9M in cash and equivalents.
- Can Capricor Therapeutics cover its short-term obligations?
- Its current ratio is 7.35 — current assets exceed current liabilities.
- Where does Capricor Therapeutics's balance sheet data come from?
- Every line is extracted from Capricor Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.